1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. HYPERPHOSPHATEMIA TREATMENT MARKET BY PRODUCT
5.1. Introduction
5.2. Sevelamer
5.3. Calcium-based Phosphate Binders
5.4. Iron-based Phosphate Binders
5.5. Lanthanum Carbonate
5.6. Others
6. HYPERPHOSPHATEMIA TREATMENT MARKET BY TEST TYPE
6.1. Introduction
6.2. Serum Phosphate Level Test
6.3. Serum Calcium Level Test
6.4. Blood Urea Nitrogen (BUN) Test
6.5. Serum Creatinine Test
6.6. Others
7. HYPERPHOSPHATEMIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. HYPERPHOSPHATEMIA TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Therapy
8.2.2. By Route of Administration
8.2.3. By Indication
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Therapy
8.3.2. By Route of Administration
8.3.3. By Indication
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Therapy
8.4.2. By Route of Administration
8.4.3. By Indication
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Therapy
8.5.2. By Route of Administration
8.5.3. By Indication
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Therapy
8.6.2. By Route of Administration
8.6.3. By Indication
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Ardelyx, Inc.
10.2. Kissei Pharmaceutical Co., Ltd.
10.3. Astellas Pharma Inc.
10.4. Chugai Pharmaceutical Co., Ltd.
10.5. Sanofi S.A.
10.6. Akebia Therapeutics, Inc.
10.7. Fresenius Medical Care AG & Co. KGaA
10.8. Vifor Pharma AG
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES